Shenzhen Neptunus Interlong Bio-Technique
Focusing on pharmaceutical and healthfood R&D, Manufacturing, Wholesale and Retail, Export & Import.
- Healthcare
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (4 %) | 3 % | (8 %) | (4 %) | (17 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 7 % | 5 % | 5 % | 3 % | 3 % | 3 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1 %) | - | (3 %) | (5 %) | (4 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Interlong is a biotechnology company focused on improving health and quality of life through innovative medical solutions. Operating primarily in China, Interlong serves a diverse range of clients including healthcare providers, pharmaceutical companies, and research institutions. The company leverages advanced biotechnology to develop high-quality products and services aimed at disease prevention and treatment. Interlong's business model revolves around research and development, manufacturing, and distribution of medical products, generating revenue through product sales and service contracts. The company benefits from China's growing emphasis on healthcare, driven by economic development and an aging population, which has led to increased domestic demand for medical solutions. Interlong's commitment to health is reflected in its mission to contribute to human health and improve people's lives through continuous innovation and high-quality offerings.
Keywords: biotechnology, healthcare, medical solutions, disease prevention, China, innovation, pharmaceuticals, research, development, quality of life.